-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background and objectivesthe recurrence of Crohn's disease (CD) after surgery is a major challengeCurcumin has an anti-inflammatory effect and promotes endoscopy in patients withulcerative colitisBased on endoscopy and clinical indicators, this study studied the efficacy of curcumin and placebo in patients treated with thiode inpreventionCD recurrencemethodsresearchers conducted a double-blind randomized controlled trial at eight referral centres in France between October 2014 and January 2018, in which 62 CD patients had a bowel ectomyThe patient satlifid thiopental (2.5 mg / kg) and was randomly divided into oral curcumin (3 g / day; n s 31) or the same placebo (n s 31) group for 6 months and then evaluated through a colonoscopyThe researchers also collected data on CD activity index, laboratory test results, and answers to the quality of life questionnaire over the six-month periodThe main endpoint was the recurrence of the CD at the 6th month of each group (Rutgeerts index score of si2)resultsin the 6th month, 18 patients (58%) who received curcumin and 21 patients receiving a placebo (68%) had postoperative recurrence (Rutgeerts index score of .i2) (P .60)Patients receiving curcumin (55%) had significantly higher rates of severe CD recurrence (Rutgeerts index of .i3) than those receiving a placebo (26%)We observed clinical recurrence of CDs in patients who received a placebo at 6 months and curcumin in 30% of patients (CD activity index score s.150) (P .80) The difference in quality of life scores for the sixth month between the groups was not significant (P - .80) Six percent of patients who received a placebo had severe adverse events, and 16 percent of patients receiving curcumin had severe adverse events (P.42) Conclusion
this study found that curcumin was no more effective than placebo in preventing CD recurrence There was no significant difference between quality of life or severe adverse events between the two groups